Current Report Filing (8-k)
May 02 2018 - 4:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 2,
2018
Foundation Medicine, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36086
|
|
27-1316416
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
150 Second Street
Cambridge, MA
|
|
02141
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code
(617)
418-2200
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of
the Securities Exchange Act of 1934
(§240.12b-2
of this
chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 2.02. Results of Operations and Financial Condition.
On May 2, 2018, Foundation Medicine, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2018.
A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form
8-K.
The information in
this Report on Form
8-K
and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press release issued by Foundation Medicine, Inc. dated May 2, 2018, furnished hereto.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
FOUNDATION MEDICINE, INC.
|
|
|
|
|
Date: May 2, 2018
|
|
|
|
By:
|
|
/s/ Robert W. Hesslein
|
|
|
|
|
|
|
|
|
Robert W. Hesslein
Senior Vice President and General Counsel
|
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Jul 2023 to Jul 2024